Join        Login             Stock Quote

What Matters This Month In Biotech For AMGN, CELG, IMGN, BMRN

 February 05, 2013 12:18 PM

(By Mani) Biotechnology stocks have always garnered interest from investors, who are on the look out for various catalysts for making their investment decisions on this stocks. Several Biotech events, including presentations, analyst days and the PDUFA dates, are considered to be one of the key catalysts for shares as the companies would be issuing updates on the events, thereby giving a birds eye-view of its upcoming products.

Following are the list of events of various biotech companies that investors should closely watch this month:

Amgen, Inc. (NASDAQ: AMGN), the largest biotechnology company in the World, is expected to conduct an analyst day on Feb.7. The company is expected to issue updates on key pipeline programs related to cancer treatments T-Vec, AMG 386 and cholesterol drug PCSK9 and commercial outlook. It may also update developments on its own biosimilar strategy on Herceptin, Avastin, Rituxan, Erbitux.

[Related -Amgen, Inc. (NASDAQ:AMGN): What Will Drive Amgen This Year?]

Investors will look at Amgen's stance on its continued long-term focus on capital allocation, and whether the company would give preference to dividends over buybacks.

Following are the key presentations to watch at Genitourinary Cancers Symposium on Feb. 14-16. Pfizer, Inc. (NYSE: PFE) is expected to present data of Axitinib in first-line on metastatic renal cell carcinoma versus Sorafenib, which is manufactured by Bayer and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) as Nexavar.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

Aragon Pharmaceuticals Inc. is expected to present its lead drug candidate ARN-509 for treatment of castration resistant prostate cancer, which has become resistant to antihormonal therapies.

Meanwhile, several companies would present clinical data's at the WORLD Orphan Symposium, which would be held during Feb 12-15.

BioMarin Pharmaceutical, Inc.(NASDAQ:BMRN) is expected to present preliminary results from on-going BMN-701 Phase I/II trial in Pompe disease, which a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle.

In addition, Synageva BioPharma Corp. (NASDAQ: GEVA) would present updated Phase II data for sebelipase alfa (SBC-102) as an enzyme replacement therapy for LAL Deficiency. Sanofi (NYSE: SNY) would unveil first positive Phase III oral data on eliglustat in Gaucher disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) would announce Phase II data on AT2220 for Pompe.

Meanwhile, investors should keep an eye on the following PDUFA dates. A PDUFA date is the deadline by which the FDA aims to complete its review of a new drug application and announce its decision on marketing approval.

Feb.10 - FDA is expected to take an action on Celgene Corporation's (NASDAQ: CELG) Pomalyst for multiple myeloma.

Feb.24 - Dynavax Technologies Corp. (NASDAQ: DVAX) is eyeing on this date as FDA would decide the fate of its U.S. Biologics License Application (BLA) for Heplisav for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age.

Feb.26 – FDA has set Feb.26 deadline for ImmunoGen, Inc.'s (Nasdaq: IMGN) Trastuzumab Emtansine (T-DM1) Marketing Application for HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.

Feb.28 – The FDA is expected to take an action on Bayer HealthCare and Onyx Pharma's New Drug Application for Stivarga (regorafenib) tablets to treat patients with metastatic and/or unresectable gastrointestinal stromal tumors.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.